The mechanism of action of avatrombopag (Sucoxin) and the scientific principle of platelet elevation

Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor (TPO-R) agonist, primarily used to treat thrombocytopenia associated with chronic liver disease and low platelets in patients with certain blood disorders. It simulates the effect of endogenous thrombopoietin (TPO) on platelet production and directly acts on hematopoietic stem cells and megakaryocyte precursors in the bone marrow, thereby promoting platelet production.

Avatrombopag targets the thrombopoietin receptor (c-Mpl) and upon binding activates the JAK-STAT signaling pathway and other downstream signaling pathways. Activating these signaling pathways can stimulate the proliferation and differentiation of megakaryocytes in the bone marrow, improve megakaryocyte maturation, and thereby enhance the production speed and number of platelets. This mechanism is highly similar to the effect of natural TPO, but avatrombopag is an oral small molecule and is more convenient to use.

By stimulating megakaryocyte proliferation and differentiation, avatrombopag rapidly increases circulating platelet numbers. Increased platelet levels not only help reduce the risk of bleeding, but also provide safe conditions for surgery or invasive treatments. In clinical studies, avatrombopag can usually significantly increase platelet counts in the short term, providing timely protection for patients in need of platelet support.

While avatrombopag increases platelets, it is still necessary to pay attention to the possible risk of thrombosis caused by excessive platelet elevation. Therefore, patients need to regularly monitor platelet levels during use and adjust the dosage under the guidance of a doctor. Rational application of avatrombopag can balance platelet count and safety, providing an effective treatment option for patients with thrombocytopenia.

Reference materials:https://www.drugs.com/